Patents Assigned to Elan Pharma International Limited
-
Patent number: 9315571Abstract: Specific binding members for Nerve Growth Factor (NGF), in particular anti-NGF antibody molecules, especially human antibody molecules, and especially those that neutralize NGF activity. Methods for using anti-NGF antibody molecules in diagnosis or treatment of NGF related disorders, including pain, asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, other diseases of airway inflammation, diabetic neuropathy, cardiac arrhythmias, HIV, arthritis, psoriasis and cancer.Type: GrantFiled: January 24, 2006Date of Patent: April 19, 2016Assignees: Elan Pharma International Limited, MedImmune LimitedInventors: Ruth Franks, Andrew Grier Buchanan, Albert George Thom, Fraser Ewing Welsh, Philip Antony Bland-Ward, Matthew Alexander Sleeman, Carl Anthony Matthews, Celia Patricia Hart, Jon Eric Hawkinson
-
Patent number: 8623412Abstract: An abuse-resistant controlled release pharmaceutical composition comprising a pharmaceutically effective amount of discrete particles of an active capable of abuse, wherein surfaces of said particles are wetted with a water insoluble coating material, and preferably wherein said composition comprises a matrix, in which said particles are distributed, and which renders the abuse-capable compound within the matrix difficult to separate from the matrix; and a method for the preparation of a controlled release pharmaceutical composition having a reduced potential for abuse, comprising applying a pressure force to a mixture comprising a water insoluble material, and particles of a pharmaceutically active compound capable of inducing in a subject a reaction that is physiologically or psychologically detrimental if administered in an immediate release dosage form, thereby resulting in surface coated particles, and incorporating said surface coated particles into a pharmaceutical composition.Type: GrantFiled: September 23, 2003Date of Patent: January 7, 2014Assignee: Elan Pharma International LimitedInventors: Vaghefi Farid, Gary G. Liversidge, Stephen B. Ruddy, Eugene R. Cooper
-
Publication number: 20120100209Abstract: The invention relates to a controlled release composition comprising a combination of isosorbide dinitrate and hydralazine, such as hydralazine hydrochloride, that in operation delivers the drug in a pulsed or multi-modal manner for the treatment of angina, ischaemic heart disease, arterial hypertension and related disease conditions. Preferably, the isosorbide dinitrate and hydralazine hydrochloride can be released from the dosage form in an erodable, diffusion and/or osmotic-controlled release profile.Type: ApplicationFiled: October 21, 2011Publication date: April 26, 2012Applicant: ELAN PHARMA INTERNATIONAL LIMITEDInventors: Gurvinder Singh Rekhi, Richard Sidwell, Sharon Hamm
-
Publication number: 20120083003Abstract: The invention provides in vitro, ex vivo, and in vivo assays for Parkin activity, in which Parkin-mediated ubiquitination of a Sept4 protein is measured. The assays may be used to screen for agents that modulate Parkin protein ligase activity.Type: ApplicationFiled: October 18, 2011Publication date: April 5, 2012Applicant: Elan Pharma International LimitedInventors: Jennifer A. Johnston, Colleen Tsui Cutcliffe
-
Patent number: 8148089Abstract: The invention provides agents and methods for treatment of diseases associated with Lewy body diseases (LBDs) in the brain of a patient. Preferred agents include inhibitors of PLK2 kinase.Type: GrantFiled: February 8, 2010Date of Patent: April 3, 2012Assignee: Elan Pharma International LimitedInventors: John P. Anderson, Kelly Banducci, Guriqbal S. Basi, David Chereau, Tamie J. Chilcote, Normand L. Frigon, Jr., Jason Goldstein, Irene Griswold
-
Publication number: 20120003319Abstract: The invention provides an oral formulation for administering to a subject comprising an imatinib compound and an enteric matrix or enteric coating or a combination thereof, whereby at least 80% of the imatinib compound is released in the small intestine of the subject. Methods of using such formulation is also provided.Type: ApplicationFiled: March 19, 2009Publication date: January 5, 2012Applicant: ELAN PHARMA INTERNATIONAL LIMITEDInventors: Gary Liversidge, Scott Jenkins
-
Patent number: 8062839Abstract: The invention provides in vitro, ex vivo, and in vivo assays for Parkin activity, in which Parkin-mediated ubiquitination of a Sept4 protein is measured. The assays may be used to screen for agents that modulate Parkin protein ligase activity.Type: GrantFiled: May 21, 2008Date of Patent: November 22, 2011Assignee: Elan Pharma International LimitedInventors: Jennifer A. Johnston, Colleen Tsui Cutcliffe
-
Publication number: 20110275999Abstract: A drug delivery device having a housing containing a gas generator controlled by an electronic controller. The gas generator generates gas into a reciprocable chamber, whereby reciprocation of the chamber causes a lever to reciprocate a pawl, and this action causes a ratchet to The device may also be provided with manually control for delivering a bolus dose Of drug when necessary.Type: ApplicationFiled: July 15, 2011Publication date: November 10, 2011Applicant: Elan Pharma International LimitedInventors: Joseph Gross, Izrail Tsals, Gilad Lavi, Gil Yigal, Ehoud Carmel
-
Publication number: 20110270218Abstract: A drug delivery device having a housing containing a gas generator controlled by an electronic controller. The gas generator generates gas into a reciprocable chamber, whereby reciprocation of the chamber causes a lever to reciprocate a pawl, and this action causes a ratchet to The device may also be provided with manually control for delivering a bolus dose of drug when necessary.Type: ApplicationFiled: July 15, 2011Publication date: November 3, 2011Applicant: ELAN PHARMA INTERNATIONAL LIMITEDInventors: Joseph Gross, Izrail Tsals, Gilad Lavi, Gil Yigal, Ehoud Carmel
-
Publication number: 20110223244Abstract: Pharmaceutical formulations that resist ethanol-induced dose dumping and methods of use thereof.Type: ApplicationFiled: March 9, 2011Publication date: September 15, 2011Applicant: Elan Pharma International LimitedInventors: Gary Liversidge, David Manser, Hardik Shah, Stephen B. Ruddy, Gurvinder Singh Rekhi
-
Patent number: 8017348Abstract: The invention provides to assays for agent useful for treatment of Parkinson's Disease. Included are cell-based assays for agents that modulate the effect of Parkin proteins on proteasome function.Type: GrantFiled: July 21, 2008Date of Patent: September 13, 2011Assignee: Elan Pharma International LimitedInventor: Jennifer A. Johnston
-
Patent number: 8003127Abstract: Compositions comprising a nanoparticulate corticosteroid and an antihistamine are described. The compositions are useful in the prophylaxis and chronic treatment of asthma in adults and pediatric patients and for the relief of allergic conjunctivitis, symptoms of seasonal allergic rhinitis in adults and pediatric patients. Combining an antihistamine with a nanoparticulate corticosteroid in a single formulation results in improved efficacy.Type: GrantFiled: March 23, 2006Date of Patent: August 23, 2011Assignee: Elan Pharma International LimitedInventors: Gary Liversidge, Scott Jenkins, H. William Bosch, Christian F. Wertz
-
Patent number: 7998117Abstract: A drug delivery device having a housing containing a gas generator controlled by an electronic controller. The gas generator generates gas into a reciprocable chamber, whereby reciprocation of the chamber causes a lever to reciprocate a pawl, and this action causes a ratchet to undergo incremental advancement. The device may also be provided with manual control for delivering a bolus dose of drug when necessary.Type: GrantFiled: May 15, 2008Date of Patent: August 16, 2011Assignee: Elan Pharma International LimitedInventors: Joseph Gross, Izrail Tsals, Gilad Lavi, Gil Yigal, Ehoud Carmel
-
Publication number: 20110177066Abstract: Passive immunotherapy methods for treating a patient having AL amyloidosis characterized by the presence of amyloid light chain-type protein fibrils.Type: ApplicationFiled: February 23, 2011Publication date: July 21, 2011Applicant: ELAN PHARMA INTERNATIONAL LIMITEDInventor: Dale B. SCHENK
-
Patent number: 7910577Abstract: Described are injectable formulations of nanoparticulate olanzapine that produce a prolonged duration of action upon administration, and methods of making and using such formulations. The injectable formulations comprise nanoparticulate olanzapine.Type: GrantFiled: November 16, 2005Date of Patent: March 22, 2011Assignee: Elan Pharma International LimitedInventors: Gary Liversidge, Scott Jenkins, Elaine Merisko Liversidge
-
Publication number: 20110064803Abstract: The present invention is directed to compositions comprising a nanoparticulate vitamin K2 having improved bioavailability. The nanoparticulate vitamin K2 particles of the composition have an effective average particle size of less than about 2000 nm and are useful in the prevention and treatment of osteoporosis. The invention also relates to a controlled release composition comprising a vitamin K2 or a nanoparticulate vitamin K2 that in operation delivers the drug in a pulsed or multi-modal manner for the prevention and treatment of osteoporosis.Type: ApplicationFiled: May 9, 2006Publication date: March 17, 2011Applicant: ELAN PHARMA INTERNATIONAL LIMITED.Inventors: John G. Devane, Paul Stark, Niall M.N. Fanning, Gurvinder Singh Rekhi, Gary Liversidge, Scott Jenkins
-
Patent number: 7825087Abstract: The present invention is directed to a composition comprising a nanoparticulate cyclosporine having improved bioavailability. The nanoparticulate cyclosporine particles of the composition have an effective average particle size of less than about 2000 nm in diameter and are useful in the prevention and treatment of organ transplant rejection and autoimmune diseases such as psoriasis, rheumatoid arthritis, and other related diseases. The invention also relates to a controlled release composition comprising a cyclosporine or a nanoparticulate cyclosporine that in operation delivers the drug in a pulsed or bimodal manner for the prevention and treatment of organ transplant rejection and autoimmune diseases such as psoriasis, rheumatoid arthritis, and other related diseases.Type: GrantFiled: April 12, 2006Date of Patent: November 2, 2010Assignee: Elan Pharma International LimitedInventors: Scott A. Jenkins, Gary Liversidge
-
Publication number: 20100260858Abstract: A composition for delivery of a drug is disclosed. The composition has a semipermeable coating, particles of a medicament having an effective average particle size of less than or about 2 ?m and at least one surface stabilizer adsorbed on the surface of the medicament particles, and a solubilizing agent.Type: ApplicationFiled: April 8, 2010Publication date: October 14, 2010Applicant: ELAN PHARMA INTERNATIONAL LIMITEDInventors: Stephen B. Ruddy, Simon L. McGurk, Rakesh Patel, John Bullock, Raj Kewalramani
-
Publication number: 20100260859Abstract: A composition for delivery of a drug is disclosed. The composition has a semipermeable coating, particles of clozapine having an effective average particle size of less than or about 2 ?m and at least one surface stabilizer adsorbed on the surface of the clozapine particles, and a solubilizing agent.Type: ApplicationFiled: April 8, 2010Publication date: October 14, 2010Applicant: ELAN PHARMA INTERNATIONAL LIMITEDInventors: Stephen B. Ruddy, Simon L. McGurk, Rakesh Patel, John Bullock, Raj Kewalramani
-
Patent number: RE41884Abstract: Disclosed are methods of intravenous administration of nanoparticulate drug formulations to a mammal to avoid adverse hemodynamic effects: by reducing the rate and concentration of the nanoparticles in the formulations; or by pre-treating the subject with histamine; or by pretreating the subject with a desensitizing amount of the nanoparticulate drug formulations.Type: GrantFiled: February 6, 2008Date of Patent: October 26, 2010Assignee: Elan Pharma International LimitedInventors: Lawrence de Garavilla, Elaine Liversidge, Gary G. Liversidge